clinical trial · NCT06940336
To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy
Qilu Pharmaceutical Co., Ltd.·phase4·recruiting·n = 15
Transthyretin Amyloid PolyneuropathyTafamidis Meglumine Soft Capsules
brief summary
The purpose of this study is to evaluate the efficacy and safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients with Transthyretin Amyloid Polyneuropathy
started
Jun 19, 2025
primary completion
Jan 1, 2028
completion
Feb 1, 2028
last updated
Jul 30, 2025
official title
A Single Arm, Multicenter, Open-label,Phase IV Clinical Study to Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients withTransthyretin Amyloid Polyneuropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol